Webinar with Dr Carlos Velez, expert trainer of the Business Development & Licensing Course for Pharma & Biotech
and The AI for Pharma Business Development & Licensing Course
FREE EDUCATIONAL WEBINAR
11 February 2027, 15:00 - 16:00 PM CET (*)
You have found the right partner for your asset. The science fits, the strategy fits and the term sheet is taking shape. But can the other side pay the upfront, fund the development plan and still be around when the milestones fall due? Will they still be around for future tech transfer? Or, are they likely to simply drop your programme in favour of something else?
Reading a set of accounts is rarely part of BD&L training. And even a partner with plenty of cash brings its own risk: big pharma can hand programmes back after a portfolio review.
In this 45-minute webinar, followed by 15 minutes of Q&A, Dr Carlos Velez shows you how much financial scrutiny different types of deals need, which few numbers really matter and where to find them. He also shows where AI tools help and where they mislead. All illustrated with real company filings and real deals. No finance background is needed.
Why attend:
Know when a partner’s financials need a close look, and when the real question is whether it will stay committed
Judge whether a partner can fund its share of the deal, even when it publishes no cash flow statement
Find out what Claude, ChatGPT and Copilot get right and wrong on real filings before you trust them with your own
Learn which checks matter for which type of partner, from cash runway and debt to going-concern warnings
What you will learn:
How a simple 2×2 grid of large and small licensors and licensees tells you which questions to ask
Which parts of the accounts answer which deal question, and where the warnings sit
Where to find financial information on private European partners, and what to request under a CDA when the public numbers are not enough
How to estimate cash burn and runway from two balance sheets, and the trap that can double your estimate
How a partner’s track record of returned and terminated deals predicts whether it will stay committed
About the expert:
Dr Carlos Velez is a seasoned expert in pharma and biotech business development and licensing, and expert trainer of the Business Development & Licensing Course for Pharma & Biotech and The AI for Pharma Business Development & Licensing Course.
Founder and Managing Partner of Lacerta Bio, an international consultancy specialising in in- and out-licensing of prescription and non-prescription product candidates and commercial products across multiple therapeutic areas and markets.
Over 10 years in senior business development roles at Penwest Pharmaceuticals, Lantic Therapeutics, Forest Labs and Genencor (now Danisco).
Author of Partnering for Growth – Business Development and Licensing in Pharma and Biotech (2025).
Highly experienced trainer and consultant, consistently praised by participants for his clear teaching and for drawing on his own deal experience.
(*) Can’t attend live? Register anyway and you will receive the recording afterwards.